Ex vivo expansion of peripheral blood progenitor cells
AssigneeKlinkum der Albert-Ludwigs-Universitat Freiberg
InventorsLothar Kanz, Woefram Brugger, Roland Mestepsmann
Life of this patent
Estimating the term…
Abstract
Patients suffering from certain types of cancer are treated by high-dose chemotherapy. In order to allow a recovery a process for the ex vivo expansion of peripheral blood progenitor cells is described, wherein CD 34.sup.+ -cells are enriched and cultivated in a medium comprising IL-1, IL-3, IL-6, EPO and SCF. The ex vivo expanded peripheral blood progenitor cells can be administered to cancer patients after chemotherapy.
Claims12
A process for ex vivo expansion of peripheral blood progenitor cells, which comprises isolating peripheral blood cells from the blood, enriching blood progenitor cells expressing the CD34 antigen, and culturing the enriched blood progenitor cells in a suitable cell growth medium to which has been added a combination of hematopoietic growth factors and cytokines consisting essentially of interleukin-1, interleukin-3, interleukin-6, erythropoietin, and stem cell growth factor.
A process for ex vivo expansion of peripheral blood progenitor cells, which comprises isolating peripheral blood cells from the blood, enriching blood progenitor cells expressing the CD34 antigen, and culturing the enriched blood progenitor cells in a suitable cell growth medium to which has been added a combination of hematopoietic growth factors and cytokines consisting essentially of interleukin-1, interleukin-3, interleukin-6, erythropoietin, stem cell growth factor, and interferon-.gamma..
Dependencies are inferred from the claim text.